RU2015142279A - Новые соединения и композиции для нацеливания на злокачественные стволовые клетки - Google Patents
Новые соединения и композиции для нацеливания на злокачественные стволовые клетки Download PDFInfo
- Publication number
- RU2015142279A RU2015142279A RU2015142279A RU2015142279A RU2015142279A RU 2015142279 A RU2015142279 A RU 2015142279A RU 2015142279 A RU2015142279 A RU 2015142279A RU 2015142279 A RU2015142279 A RU 2015142279A RU 2015142279 A RU2015142279 A RU 2015142279A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- pharmaceutical composition
- composition
- particles
- hplc
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 13
- 239000000203 mixture Substances 0.000 title claims 11
- 230000003211 malignant effect Effects 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000002245 particle Substances 0.000 claims 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 5
- 238000005481 NMR spectroscopy Methods 0.000 claims 5
- 238000004128 high performance liquid chromatography Methods 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 239000012535 impurity Substances 0.000 claims 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- 235000019439 ethyl acetate Nutrition 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229940125904 compound 1 Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013557 residual solvent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31588610P | 2010-03-19 | 2010-03-19 | |
| US31589010P | 2010-03-19 | 2010-03-19 | |
| US61/315,890 | 2010-03-19 | ||
| US61/315,886 | 2010-03-19 | ||
| US32581410P | 2010-04-19 | 2010-04-19 | |
| US61/325,814 | 2010-04-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012144421/04A Division RU2571661C2 (ru) | 2010-03-19 | 2011-03-21 | Новые соединения и композиции для нацеливания на злокачественные стволовые клетки |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015142279A true RU2015142279A (ru) | 2018-12-28 |
| RU2015142279A3 RU2015142279A3 (enExample) | 2019-02-26 |
Family
ID=50940329
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015142279A RU2015142279A (ru) | 2010-03-19 | 2011-03-21 | Новые соединения и композиции для нацеливания на злокачественные стволовые клетки |
| RU2016123004A RU2657750C1 (ru) | 2010-03-19 | 2011-03-21 | Новые способы направленного воздействия на раковые стволовые клетки |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016123004A RU2657750C1 (ru) | 2010-03-19 | 2011-03-21 | Новые способы направленного воздействия на раковые стволовые клетки |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP3108750B1 (enExample) |
| JP (11) | JP2014098050A (enExample) |
| CN (3) | CN104016951B (enExample) |
| CA (3) | CA2959931A1 (enExample) |
| DK (1) | DK3108750T3 (enExample) |
| ES (1) | ES2689928T3 (enExample) |
| HU (1) | HUE066482T2 (enExample) |
| NZ (2) | NZ712826A (enExample) |
| PT (1) | PT2547205T (enExample) |
| RU (2) | RU2015142279A (enExample) |
| SG (3) | SG10201706265PA (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104586832B (zh) | 2007-09-10 | 2018-02-16 | 北京强新生物科技有限公司 | 用于癌症治疗的组合物和方法 |
| SG10201706265PA (en) * | 2010-03-19 | 2017-08-30 | Boston Biomedical Inc | Novel compounds and compositions for targeting cancer stem cells |
| CN103025159A (zh) * | 2010-03-19 | 2013-04-03 | 波士顿生物医学公司 | 靶向癌症干细胞的新方法 |
| KR20150139955A (ko) | 2013-04-09 | 2015-12-14 | 보스톤 바이오메디칼, 인크. | 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온 |
| WO2016196935A1 (en) * | 2015-06-03 | 2016-12-08 | Boston Biomedical, Inc. | Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer |
| GB201515387D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| GB201515391D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| JP6751658B2 (ja) | 2016-11-15 | 2020-09-09 | クラリオン株式会社 | 音声認識装置、音声認識システム |
| JP7106563B2 (ja) | 2016-11-29 | 2022-07-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | ナフトフラン誘導体、その調製、および使用方法 |
| WO2018213424A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61205257A (ja) * | 1985-03-08 | 1986-09-11 | Ishihara Sangyo Kaisha Ltd | ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤 |
| EP0945131A1 (de) * | 1998-03-27 | 1999-09-29 | Boehringer Ingelheim Pharma KG | Perorale Wirkstoff-Suspension |
| EP1146869A2 (en) * | 1999-01-27 | 2001-10-24 | University Of South Florida | Inhibition of stat3 signal transduction for human cancer therapy |
| EP1551392A4 (en) * | 2002-09-17 | 2006-09-20 | Arqule Inc | NEW LAPACHO COMPOUNDS AND APPLICATION METHOD THEREFOR |
| AR042052A1 (es) * | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| US8623405B2 (en) * | 2005-01-28 | 2014-01-07 | Takeda Pharmaceutical Company Limited | Finely divided composition containing poorly water soluble substance |
| JP2006290871A (ja) * | 2005-03-16 | 2006-10-26 | Taheebo Japan Kk | 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法 |
| US20080255193A1 (en) * | 2005-09-30 | 2008-10-16 | Jeffrey Brum | Pharmaceutical Composition |
| EP1860126A1 (en) * | 2006-05-26 | 2007-11-28 | INEOS Manufacturing Belgium NV | Polyolefin powder |
| CN104586832B (zh) * | 2007-09-10 | 2018-02-16 | 北京强新生物科技有限公司 | 用于癌症治疗的组合物和方法 |
| US8822482B2 (en) * | 2008-07-08 | 2014-09-02 | Beta Pharma, Inc. | Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof |
| SG10201706265PA (en) * | 2010-03-19 | 2017-08-30 | Boston Biomedical Inc | Novel compounds and compositions for targeting cancer stem cells |
| DK2547334T3 (en) * | 2010-03-19 | 2018-02-19 | 1Globe Biomedical Co Ltd | NEW CONNECTIONS AND COMPOSITIONS FOR TARGETING CANCER STAM CELLS |
| CN103025159A (zh) * | 2010-03-19 | 2013-04-03 | 波士顿生物医学公司 | 靶向癌症干细胞的新方法 |
-
2011
- 2011-03-21 SG SG10201706265PA patent/SG10201706265PA/en unknown
- 2011-03-21 PT PT117571356T patent/PT2547205T/pt unknown
- 2011-03-21 SG SG10201704745UA patent/SG10201704745UA/en unknown
- 2011-03-21 EP EP16182813.2A patent/EP3108750B1/en active Active
- 2011-03-21 NZ NZ712826A patent/NZ712826A/en unknown
- 2011-03-21 HU HUE11757135A patent/HUE066482T2/hu unknown
- 2011-03-21 RU RU2015142279A patent/RU2015142279A/ru not_active Application Discontinuation
- 2011-03-21 CA CA2959931A patent/CA2959931A1/en not_active Abandoned
- 2011-03-21 CN CN201410101861.9A patent/CN104016951B/zh active Active
- 2011-03-21 CA CA2959951A patent/CA2959951A1/en not_active Abandoned
- 2011-03-21 RU RU2016123004A patent/RU2657750C1/ru active
- 2011-03-21 ES ES16182813.2T patent/ES2689928T3/es active Active
- 2011-03-21 NZ NZ701237A patent/NZ701237A/en not_active IP Right Cessation
- 2011-03-21 CN CN201710134235.3A patent/CN106860443A/zh active Pending
- 2011-03-21 EP EP17196754.0A patent/EP3295796A1/en active Pending
- 2011-03-21 CA CA2993363A patent/CA2993363A1/en not_active Abandoned
- 2011-03-21 SG SG10201502079VA patent/SG10201502079VA/en unknown
- 2011-03-21 DK DK16182813.2T patent/DK3108750T3/en active
- 2011-03-21 CN CN201710613672.3A patent/CN107311969B/zh active Active
-
2014
- 2014-03-03 JP JP2014040227A patent/JP2014098050A/ja not_active Withdrawn
- 2014-03-03 JP JP2014040226A patent/JP2014098049A/ja not_active Withdrawn
- 2014-03-03 JP JP2014040225A patent/JP5993390B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-25 JP JP2015035285A patent/JP2015098489A/ja active Pending
- 2015-09-11 JP JP2015179115A patent/JP6246169B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-30 JP JP2016194176A patent/JP2016222723A/ja not_active Withdrawn
-
2017
- 2017-10-13 JP JP2017199380A patent/JP2018002744A/ja not_active Withdrawn
-
2018
- 2018-04-20 JP JP2018081329A patent/JP2018115209A/ja not_active Withdrawn
-
2020
- 2020-01-31 JP JP2020014705A patent/JP2020063308A/ja not_active Withdrawn
- 2020-05-08 JP JP2020082479A patent/JP2020114888A/ja active Pending
-
2021
- 2021-12-06 JP JP2021197732A patent/JP2022020002A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012144421A (ru) | Новые соединения и композиции для нацеливания на злокачественные стволовые клетки | |
| DK2125705T3 (en) | Crystalline minocycline base and processes for their preparation | |
| CA3097949C (en) | Hpk1 inhibitors, preparation method and application thereof | |
| RU2008129821A (ru) | Гетероциклические производные в качестве модуляторов ионных каналов | |
| WO2009136995A3 (en) | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors | |
| KR20150139854A (ko) | 피롤 유도체의 결정 및 그 제조 방법 | |
| EP2364312A2 (en) | Preparation of crystalline palonosetron hydrochloride | |
| JP2014098050A5 (enExample) | ||
| CA2268126A1 (en) | Quinolines and their therapeutic use | |
| WO2012024682A1 (en) | Ship1 modulators and related methods | |
| US9624207B2 (en) | Polymorphs of azilsartan medoxomil | |
| CN103214454A (zh) | 一种比拉斯汀晶型及制备方法 | |
| WO2010113179A3 (en) | Process for purifying eslicarbazepine acetate | |
| ME02480B (me) | Optimizirana sinteza čistih, nepolimorfnih, kristalnih žučnih kiselina sa određenom veličinom čestica | |
| CN103553984A (zh) | 美索舒利晶型及其制备方法 | |
| JP5793134B2 (ja) | ペリレンテトラカルボン酸ジイミド化合物を含有してなる有機半導体材料、及び有機半導体素子 | |
| CN104662019A (zh) | 制备阿齐沙坦奥美沙坦酯的高纯度钾盐的方法 | |
| CN103896763A (zh) | 一种2-（α-羟基戊基）苯甲酸钾多晶型及其制备方法、制剂与应用 | |
| US20140378472A1 (en) | Amorphous vilazodone hydrochloride, a process for its preparation and pharmaceutical compositions thereof | |
| CN103319422A (zh) | 一种吉非替尼新晶型及其制备方法 | |
| JP2013503823A5 (enExample) | ||
| WO2018072742A1 (zh) | 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法 | |
| RU2011143805A (ru) | Кристаллы гидробромата прасугреля | |
| WO2007110734A1 (en) | Process for the preparation of tadalafil | |
| WO2014195977A2 (en) | Novel polymorphs of vismodegib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200114 |